Hydroxycamptothecin

Summary

Hydroxycamptothecin (CHEMBL273862) is a phase-3 clinical-stage small molecule; indicated across 1 condition including hepatocellular carcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 364.4 Da · C20H16N2O5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL273862
Name	Hydroxycamptothecin
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	97226
Molecular formula	C20H16N2O5
Molecular weight	364.4
InChIKey	HAWSQZCWOQZXHI-FQEVSTJZSA-N

SMILES: CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=C(C3=C2)N=C5C=CC(=CC5=C4)O)O

IUPAC name: (19S)-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione

Also known as: Hydroxycamptothecin, Irinotecan related compound a, NSC-107124, SID26750003, SID407052, Hydroxycamptothecine, HYDROXYCAMPTOTHECIN

Patent coverage: 4,348 distinct patent families (11,312 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 10,849 (96%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 10 (assay-derived). Sample: Nuclear receptor ROR-gamma, Survival motor neuron protein, Inositol monophosphatase 1, Ferritin light chain, DNA topoisomerase 1, Menin/Histone-lysine N-methyltransferase MLL, Cytochrome P450 3A4, Caspase-7, Hemoglobin subunit beta, Caspase-1.

Bioactivity

ChEMBL activities: 5 potent at pChembl ≥ 5 of 12 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
SMN1	7.3	Potency	50.1	nM	CHEMBL_ACT_3867044
TOP1	6.96	IC50	110	nM	CHEMBL_ACT_928312
P51450	5.8	Potency	1585	nM	CHEMBL_ACT_4790617
P51450	5.15	Potency	7080	nM	CHEMBL_ACT_4098291
P97697	5	Potency	10000	nM	CHEMBL_ACT_4419348

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hepatocellular carcinoma	3	MONDO:0007256	EFO:0000182

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07424287	PHASE3	NOT_YET_RECRUITING	A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).